Nexien BioPharma, Inc. (NXEN) financial statements (2022 and earlier)

Company profile

Business Address 4340 E KENTUCKY AVE
GLENDALE, CO 80246
State of Incorp. DE
Fiscal Year End June 30
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
TTM
6/30/2021
6/30/2020
6/30/2019
6/30/2018
6/30/2017
6/30/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments31811146820  
Cash and cash equivalents31811146820  
Receivables    15  
Prepaid expense 8     
Other current assets  1265   
Other undisclosed current assets   100   
Total current assets:32623311835  
Noncurrent Assets
Long-term investments and receivables    100  
Due from related parties    100  
Other undisclosed noncurrent assets    338  
Total noncurrent assets:    438  
TOTAL ASSETS:326233111,272  
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:7617458912 
Accrued liabilities     12 
Other undisclosed accounts payable and accrued liabilities76174589  
Debt241312    
Due to related parties3520   60 
Other undisclosed current liabilities     1970
Total current liabilities:65392945899270
Noncurrent Liabilities
Total liabilities:65392945899270
Stockholders' equity
Stockholders' equity attributable to parent, including:(62)(14)(6)2661,184(92)(70)
Common stock6655422
Additional paid in capital10,54610,47611,58311,5062,88300
Accumulated deficit(10,649)(10,307)(8,447)(5,776)(1,475)(94)(72)
Other undisclosed stockholders' equity attributable to parent35(188)(3,148)(5,470)(229)  
Total stockholders' equity:(62)(14)(6)2661,184(92)(70)
TOTAL LIABILITIES AND EQUITY:326233111,272  

Income statement (P&L) ($ in thousands)

12/31/2021
TTM
6/30/2021
6/30/2020
6/30/2019
6/30/2018
6/30/2017
6/30/2016
Operating expenses(285)(1,844)(2,672)(4,301)(1,283)(16)(16)
Other operating expense, net
(Other Expenses)
     (6)(5)
Operating loss:(285)(1,844)(2,672)(4,301)(1,283)(22)(21)
Nonoperating expense
(Other Nonoperating expense)
(32)(16)(0)    
Interest and debt expense(5)(3)(0)  (6)(5)
Net loss:(322)(1,863)(2,672)(4,301)(1,283)(28)(26)
Other undisclosed net income attributable to parent930  65
Net loss available to common stockholders, diluted:(312)(1,860)(2,672)(4,301)(1,283)(22)(21)

Comprehensive Income ($ in thousands)

12/31/2021
TTM
6/30/2021
6/30/2020
6/30/2019
6/30/2018
6/30/2017
6/30/2016
Net loss:(322)(1,863)(2,672)(4,301)(1,283)(28)(26)
Comprehensive loss, net of tax, attributable to parent:(322)(1,863)(2,672)(4,301)(1,283)(28)(26)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: